MDXHEALTH SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.14 USD | +5.72% |
|
+27.13% | -20.30% |
| 05-01 | MDxHealth SA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-01 | Transcript : MDxHealth SA, Q1 2024 Earnings Call, May 01, 2024 |
| Sales 2023 | 64.39M 69.29M 5.53B | Sales 2024 * | 78.66M 84.65M 6.75B | Capitalization | 79.54M 85.59M 6.83B |
|---|---|---|---|---|---|
| Net income 2023 | -39M -41.97M -3.35B | Net income 2024 * | -26M -27.98M -2.23B | EV / Sales 2023 | 1.51 x |
| Net cash position 2023 * | - 0 0 | Net Debt 2024 * | 103.27 111.13 8.86K | EV / Sales 2024 * | 1.01 x |
| P/E ratio 2023 |
-2.37
x | P/E ratio 2024 * |
-3.2
x | Employees | 255 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 97.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on MDxHealth SA
More press releases
| 1 day | +5.72% | ||
| 1 week | +27.13% | ||
| Current month | +25.60% | ||
| 1 month | +13.77% | ||
| 3 months | -18.86% | ||
| 6 months | +25.60% | ||
| Current year | -20.30% |
1 week
2.46
3.20
1 month
2.213.20
Current year
2.214.64
1 year
2.214.64
3 years
0.0017.80
5 years
0.0017.80
10 years
0.0062.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 3.14 | +5.72% | 169,445 |
| 02/05/24 | 2.97 | +11.24% | 120,390 |
| 01/05/24 | 2.67 | +6.80% | 45,899 |
| 30/04/24 | 2.5 | 0.00% | 6,525 |
| 29/04/24 | 2.5 | +1.21% | 24,790 |
Delayed Quote Nasdaq, May 03, 2024 at 09:30 pm
More quotes
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Companyâs tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Calendar
29/05/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.14
USD
Average target price
7
USD
Spread / Average Target
+122.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.30% | 85.68M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- MDXH Stock
